Wong 2012.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 141 adults and elderly (macrolide n = 71, placebo n = 70) Age in years (mean ± SD): macrolide: 60.9 ± 13.6, placebo: 59.0 ± 13.3 Setting: secondary care
Interventions	Indication: non‐cystic fibrosis bronchiectasis Type of macrolide: azithromycin Route: per oral Dose: 500 mg 3 times a week Duration of treatment: 6 months Total treatment dose: 39,000 mg
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: yes Adverse events ascertainment: participant asked Adverse events: data reported Antimicrobial resistance: reported on participants diagnosed with macrolide‐resistant Streptococcus pneumoniae following macrolide treatment Death: not reported
Funding sources	Study funded by the Health Research Council of New Zealand and the Auckland District Health Board Charitable Trust.
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants, clinicians, and investigators blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	6% in macrolide group versus 10% in placebo group withdrew. However, reasons for dropout are clearly presented.
Selective reporting (reporting bias)	Unclear risk	Adverse events stated as an outcome, standardised ascertainment, and adverse events reported. Note that only adverse events with an incidence of more than 2.5% in either group were presented.
Other bias	Low risk	None were identified.